Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia

Frontiers in Pharmacology

Volumn 3 MAY, Issue , 2012, Pages

  Caballero, Adriana ^a   Tseng, Kuei Y ^a  

^a Chicago Medical School RFUMS   (United States)

Author keywords

Adolescence; Cannabinoids; Prefrontal cortex; Schizophrenia

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DOPAMINE; ENDOCANNABINOID; GLUTAMIC ACID; SEROTONIN;

4 AMINOBUTYRIC ACID RELEASE; AMNESIA; ANIMAL BEHAVIOR; ARTICLE; BRAIN DEVELOPMENT; BRAIN DYSFUNCTION; BRAIN FUNCTION; BRAIN REGION; CANNABIS SMOKING; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; DEVELOPMENTAL STAGE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISORIENTATION; ENZYME INACTIVATION; ENZYME INHIBITION; EXECUTIVE FUNCTION; GRAY MATTER; HUMAN; INTERNEURON; INTRACELLULAR SIGNALING; MENTAL DISEASE; NERVE CELL NETWORK; NONHUMAN; PARANOIA; PATTERN RECOGNITION; PERCEPTION DISORDER; POSITIVE SYNDROME; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REGULATORY MECHANISM; SCHIZOPHRENIA; SOCIAL DISCRIMINATION; SOCIAL INTERACTION; SYMPTOMATOLOGY; THINKING IMPAIRMENT;

EID: 84866014815     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00101     Document Type: Article

References (69)

1. Abush, H., and Akirav, I. (2012). Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. PLoS ONE 7, e31731. doi:10.1371/journal.pone. 0031731
2. Andersen, S. L. (2003). Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci. Biobehav. Rev. 27, 3-18.
3. Armstrong, C., and Soltesz, I. (2012). Basket cell dichotomy in microcircuit function. J. Physiol. (Lond.) 590, 683-694.
4. Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., and Moffitt, T. E. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325, 1212-1213.
5. Arseneault, L., Cannon, M., Witton, J., and Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184, 110-117.
6. Berrendero, F., Garcia-Gil, L., Hernandez, M. L., Romero, J., Cebeira, M., De Miguel, R., Ramos, J. A., and Fernandez-Ruiz, J. J. (1998). Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 125, 3179-3188
7. Bodor, A. L., Katona, I., Nyiri, G., Mackie,K.,Ledent,C.,Hajos,N.,and Freund, T. F. (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J. Neurosci. 25, 6845-6856.
8. Bortolato, M., Aru, G. N., Frau, R., Orru, M., Luckey, G. C., Boi, G., and Gessa, G. L. (2005). The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl.) 177, 264-271.
9. Buzsaki, G., and Draguhn, A. (2004). Neuronal oscillations in cortical networks. Science 304, 1926-1929.
10. Casey, B. J., Giedd, J. N., and Thomas, K. M. (2000). Structural and functional brain development and its relation to cognitive development. Biol. Psychol. 54, 241-257.
11. Caspi, A., Moffitt, T. E., Cannon, M., Mcclay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., and Craig, I. W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57, 1117-1127.
12. Chambers, R. A., Taylor, J. R., and Potenza, M. N. (2003). Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am.J.Psychiatry 160, 1041-1052.
13. Crews, F., He, J., and Hodge, C. (2007). Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol. Biochem. Behav. 86, 189-199.
14. D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., and Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57, 594-608.
15. D'Souza, D. C., Fridberg, D. J., Skosnik, P. D., Williams, A., Roach, B., Singh, N., Carbuto, M., Elander, J., Schnakenberg, A., Pittman, B., Sewell, R. A., Ranganathan, M., and Mathalon, D. (2012). Doserelated modulation of event-related potentials to novel and target stimuli by intravenous delta(9)-THC in humans. Neuropsychopharmacology. 37, doi:10.1038/npp.2012.8
16. D'Souza, D. C., Perry, E., Macdougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., and Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
17. Egertova, M., and Elphick, M. R. (2000). Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J. Comp. Neurol. 422, 159-171.
18. Eggan, S. M., Melchitzky, D. S., Sesack, S. R., Fish, K. N., and Lewis, D. A. (2010). Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 169, 1651-1661.
19. Ehrenreich, H., Rinn, T., Kunert, H. J., Moeller, M. R., Poser, W., Schilling, L., Gigerenzer, G., and Hoehe, M. R. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl.) 142, 295-301.
20. Elsohly, M. A., and Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78, 539-548
21. Fontes, M. A., Bolla, K. I., Cunha, P. J., Almeida, P. P., Jungerman, F., Laranjeira, R. R., Bressan, R. A., and Lacerda, A. L. (2011). Cannabis use before age 15 and subsequent executive functioning. Br. J. Psychiatry 198, 442-447.
22. Fortin, D. A., and Levine, E. S. (2007). Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb. Cortex 17, 163-174.
23. Fortin, D. A., Trettel, J., and Levine, E. S. (2004). Brief trains of action potentials enhance pyramidal neuron excitability via endocannabinoid-mediated suppression of inhibition. J. Neurophysiol. 92, 2105-2112.
24. Freund, T. F. (2003). Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci. 26, 489-495.
25. Galarreta, M., Erdelyi, F., Szabo, G., and Hestrin, S. (2008). Cannabinoid sensitivity and synaptic properties of 2 GABAergic networks in the neocortex. Cereb. Cortex 18, 2296-2305
26. Hajos, M., Hoffmann, W. E., and Kocsis, B. (2008). Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol. Psychiatry 63, 1075-1083.
27. Harkany, T., Guzman, M., Galve Roperh, I., Berghuis, P., Devi, L. A., and Mackie, K. (2007). The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 28, 83-92.
28. Harkany, T., Holmgren, C., Hartig, W., Qureshi, T., Chaudhry, F. A., Storm-Mathisen, J., Dobszay, M. B., Berghuis, P., Schulte, G., Sousa, K. M., Fremeau, R. T. Jr., Edwards, R. H., Mackie, K., Ernfors, P., and Zilberter, Y. (2004). Endocannabinoid-independent retrograde signaling at inhibitory synapses in layer 2/3 of neocortex: involvement of vesicular glutamate transporter 3. J. Neurosci. 24, 4978-4988.
29. Hart, C. L., Van Gorp, W., Haney, M., Foltin, R. W., and Fischman, M. W. (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 25, 757-765.
30. Heng, L., Beverley, J. A., Steiner, H., and Tseng, K. Y. (2011). Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 65, 278-286
31. Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Fananas, L., Drukker, M., Ramaekers, J. G., and Van Os, J. (2006). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748-2757.
32. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., De Costa, B. R., and Rice, K. C. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
33. Hestrin, S., and Galarreta, M. (2005). Electrical synapses define networks of neocortical GABAergic neurons. Trends Neurosci. 28, 304-309.
34. Hill, E. L., Gallopin, T., Ferezou, I., Cauli, B., Rossier, J., Schweitzer, P., and Lambolez, B. (2007). Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J. Neurophysiol. 97, 2580-2589.
35. Ilan, A. B., Smith, M. E., and Gevins, A. (2004). Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl.) 176, 214-222.
36. Iversen, L. (2003). Cannabis and the brain. Brain 126, 1252-1270.
37. Katona, I., and Freund, T. F. (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14, 923-930
38. Katona, I., Sperlagh, B., Sik, A., Kafalvi, A.,Vizi,E. S.,Mackie,K.,and Freund, T. F. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19, 4544-4558.
39. Kreitzer, A. C., and Regehr, W. G. (2002). Retrograde signaling by endocannabinoids. Curr. Opin. Neurobiol. 12, 324-330.
40. Kucewicz, M. T., Tricklebank, M. D., Bogacz, R., and Jones, M. W. (2011). Dysfunctional prefrontal cortical network activity and interactions following cannabinoid receptor activation. J. Neurosci. 31, 15560-15568
41. Lodge, D. J., Behrens, M. M., and Grace, A. A. (2009). A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J. Neurosci. 29, 2344-2354
42. Lovinger, D. M. (2008). Presynaptic modulation by endocannabinoids. Handb. Exp. Pharmacol. 435-477.
43. Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G.,Gutierrez,S. O.,Van Der Stelt,M., Lopez-Rodriguez, M. L., Casanova, E., Schutz, G., Zieglgansberger, W., Di Marzo, V., Behl, C., and Lutz, B. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88.
44. Marsicano, G., and Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11, 4213-4225.
45. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
46. Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319-328.
47. O'Shea, M., Singh, M. E., Mcgregor, I. S., and Mallet, P. E. (2004). Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. (Oxford) 18, 502-508.
48. Pettit, D. A., Harrison, M. P., Olson, J. M., Spencer, R. F., and Cabral, G. A. (1998). Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51, 391-402.
49. Pope,H.G.Jr.,Gruber,A.J.,Hudson, J. I., Cohane, G., Huestis, M. A., and Yurgelun-Todd, D. (2003). Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 69, 303-310.
50. Quinn, H. R., Matsumoto, I., Callaghan, P. D., Long, L. E., Arnold, J. C., Gunasekaran, N., Thompson, M. R., Dawson, B., Mallet, P. E., Kashem, M. A., Matsuda-Matsumoto, H., Iwazaki, T., and Mcgregor, I. S. (2008). Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33, 1113-1126.
51. Rissling, A. J., Makeig, S., Braff, D. L., and Light, G. A. (2010). Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr. Psychiatry Rep. 12, 572-578.
52. Robbe, D., Montgomery, S. M., Thome, A., Rueda-Orozco, P. E., Mcnaughton, B. L., and Buzsaki, G. (2006). Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat. Neurosci. 9, 1526-1533.
53. Rodriguez de Fonseca, F., Ramos, J. A., Bonnin, A., and Fernandez-Ruiz, J. J. (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4, 135-138.
54. Schneider, M., and Koch, M. (2003). Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28, 1760-1769.
55. Schneider, M., Schomig, E., and Leweke, F. M. (2008). Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 13, 345-357.
56. Sewell, R. A., Ranganathan, M., and D'Souza, D. C. (2009). Cannabinoids and psychosis. Int. Rev. Psychiatry 21, 152-162.
57. Sohal, V. S., Zhang, F., Yizhar, O., and Deisseroth, K. (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698-702.
58. Spear, L. P. (2000). The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24, 417-463.
59. Spencer, K. M., Nestor, P. G., Niznikiewicz, M. A., Salisbury, D. F., Shenton, M. E., and Mccarley, R. W. (2003). Abnormal neural synchrony in schizophrenia. J. Neurosci. 23, 7407-7411.
60. Trettel, J., and Levine, E. S. (2002). Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J. Neurophysiol. 88, 534-539.
61. Trettel, J., and Levine, E. S. (2003). Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J. Neurophysiol. 89, 2334-2338.
62. Tseng, K. Y., Chambers, R. A., and Lipska, B. K. (2009). The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 204, 295-305.
63. Uhlhaas, P. J., and Singer, W. (2006). Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52, 155-168.
64. Uhlhaas, P. J., and Singer, W. (2010). Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 11, 100-113.
65. Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E., and Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61, 352-355.
66. Volman, V., Behrens, M. M., and Sejnowski, T. J. (2011). Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J. Neurosci. 31, 18137-18148.
67. Wedzony, K., and Chocyk, A. (2009). Cannabinoid CB1 receptors in rat medial prefrontal cortex are colocalized with calbindinbut not parvalbumin- and calretinin-positive GABA-ergic neurons. Pharmacol. Rep. 61, 1000-1007.
68. Wilson, W., Mathew, R., Turkington, T., Hawk, T., Coleman, R. E., and Provenzale, J. (2000). Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J. Addict. Dis. 19, 1-22.
69. Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., and Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325, 1199.